Beijing Tong Ren Tang Chinese Medicine Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Wang Chi
Chief executive officer
HK$1.2m
Total compensation
| CEO salary percentage | 87.86% |
| CEO tenure | 1yr |
| CEO ownership | n/a |
| Management average tenure | 1.4yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | HK$1m | HK$1m | HK$500m |
Compensation vs Market: Wang's total compensation ($USD148.44K) is below average for companies of similar size in the German market ($USD1.25M).
Compensation vs Earnings: Insufficient data to compare Wang's compensation with company performance.
CEO
Wang Chi (49 yo)
Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 1.4yrs | no data | no data | |
| CEO & Executive Director | 1yr | HK$1.16m | no data | |
| Executive Vice Chairman | no data | no data | no data | |
| CFO & Company Secretary | 5yrs | no data | no data | |
| Deputy GM & General Counsel | no data | no data | no data | |
| Executive Director | no data | no data | no data |
Experienced Management: TQR's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 1.4yrs | no data | no data | |
| CEO & Executive Director | 1yr | HK$1.16m | no data | |
| Executive Vice Chairman | no data | no data | no data | |
| Executive Director | no data | no data | no data | |
| Independent Non-Executive Director | 7.7yrs | HK$288.00k | no data | |
| Independent Non-Executive Director | 12.1yrs | HK$288.00k | no data | |
| Non-Executive Director | 2.8yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | HK$288.00k | no data |
Experienced Board: TQR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 17:53 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Tong Ren Tang Chinese Medicine Company Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| null null | CMB International Securities Limited |
| Zhou Chen | HSBC |